Título del proyecto: Deciphering the mechanisms of Radioresistance: Functional interplay between transcription and replication stress in the cellular hierarchies of Glioblastoma. PID2022-136824OA-I00
Financiación: 175.000 €
Organismo financiador: Proyectos Generación del Conocimiento 2022. Ministerio Ciencia e Innovación
Resumen: The research project investigates the brain tumour known as Glioblastoma (GBM). Glioblastoma remains one of the most aggressive and lethal brain cancers, with a high recurrence rate due to the resistance of a cell subpopulation called Glioblastoma Stem-like Cells (GSCs). This subpopulation of GSCs possesses an efficient capacity to repair DNA damage after conventional treatments, which makes them resistant to current therapies. Our aim is focused on how the genomic architecture of different cell subpopulations, particularly glioblastoma stem cells, influences their ability to respond differentially to DNA damage, highlighting the critical role of the genome in cellular damage response mechanisms and DNA repair processes.
IP: Diana Aguilar Morante
Otro personal adscrito al proyecto:
- Candela Arribas Parejas
- Miriam Alonso García
- Yi Chieh Lim
--------------------------------
Título del proyecto: EMERGIA Program_EMC21_00385. Fight against therapeutic resistance in Glioblastoma tumours using genomic instability as ally.
Financiación: 237.008 €
Organismo financiador: Consejería de Universidad, Investigación e Innovación-Junta de Andalucía
IP: Diana Aguilar Morante
--------------------------------
Título del proyecto: CSyF-2022-Proyectos (24664 Ref-PI-0034-2022) Fight against therapeutic resistance in High-Risk Neuroblastoma using genomic instability as ally.
Financiación: 40.250 €
Organismo financiador: Consejería Salud y Familias-Junta de Andalucía
IP: Diana Aguilar Morante and Ricardo Pardal Redondo.
--------------------------------
Título del proyecto: Investigador AECC 2022. Unravelling functional interplay between R-loops and Replication-Transcription Conflicts as a novel therapeutic target in High-Risk neuroblastoma tumours.
Financiación: 200.000 €
Organismo financiador: Fundación Española Contra el Cáncer (AECC)
IP: Diana Aguilar Morante
